Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates Equivalent Affinity and Functional Blockade of Glycoprotein IIb/IIIa and α v β 3 Integrins
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Background —Large, randomized, and blinded clinical trials (EPIC, EPILOG, and CAPTURE) have demonstrated that abciximab (ReoPro, chimeric 7E3 Fab) markedly reduces thrombotic events associated with percutaneous transluminal coronary interventions. The marked early benefits at 30 days were sustained at 6 months and 3 years. Initially developed because of its efficacy in blocking GP IIb/IIIa (α IIb /β 3 ) receptors on platelets, abciximab also binds with equivalent affinity to α v β 3 . Methods and Results —This study presents a detailed characterization of the α v β 3 interaction, including the ability of abciximab to (1) bind with comparable affinity to α v β 3 and GP IIb/IIIa, (2) inhibit α v β 3 and GP IIb/IIIa–mediated cell adhesion in vitro with IC 50 values approximating binding K D values, and (3) redistribute between GP IIb/IIIa and α v β 3 integrins in vitro. Conclusions —As an antagonist of not only GP IIb/IIIa but also α v β 3 , abciximab may provide additional clinical benefit in preventing α v β 3 -mediated effects such as thrombin generation, clot retraction, or smooth muscle cell migration and proliferation. Abciximab binds with equivalent affinity to both GP IIb/IIIa and α v β 3 and redistributes between the 2 integrin receptors in vitro. Abciximab has been previously shown to circulate on platelets for up to 2 weeks. Taken together, these findings suggest that abciximab may have the ability to inhibit both GP IIb/IIIa and α v β 3 for extended periods.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Requirement of Vascular Integrin α v β 3 for Angiogenesis
Brooks, P. C., Clark, R. A. F., & Cheresh, D. A. (1994) · Science · doi:10.1126/science.7512751 · Cited by 3,020
(1994) · New England Journal of Medicine · doi:10.1056/nejm199404073301402 · Cited by 2,589
(1997) · New England Journal of Medicine · doi:10.1056/nejm199706123362401 · Cited by 1,883
Giachelli, C. M., Bae, N., Almeida, M., Denhardt, D. T., Alpers, C. E., & Schwartz, S. M. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116755 · Cited by 641
Liaw, L., Skinner, M. P., Raines, E. W., Ross, R., Cheresh, D. A., Schwartz, S. M., & Giachelli, C. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117718 · Cited by 512
Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets
Wagner, C., Mascelli, M., Neblock, D., Weisman, H., Coller, B., & Jordan, R. (1996) · Blood · doi:10.1182/blood.v88.3.907.907 · Cited by 460
Self-citationIntegrin alpha v beta 3 rescues melanoma cells from apoptosis in three-dimensional dermal collagen.
Montgomery, A. M., Reisfeld, R. A., & Cheresh, D. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.19.8856 · Cited by 448
Reverter, J. C., Béguin, S., Kessels, H., Kumar, R., Hemker, H. C., & Coller, B. S. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118859 · Cited by 393
Wayner, E. A., Orlando, R. A., & Cheresh, D. A. (1991) · The Journal of cell biology · doi:10.1083/jcb.113.4.919 · Cited by 358
Cited by
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.181940 · Cited by 1,853
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.02.013 · Cited by 1,510
Targeting integrin pathways: mechanisms and advances in therapy
Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., Gu, Y., Zhao, N., Xiang, Q., & Cui, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01259-6 · Cited by 1,275
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00889-5 · Cited by 963
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.01.014 · Cited by 960
Ishikawa, M., & Hashimoto, Y. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101356p · Cited by 619
Emerging therapeutic opportunities for integrin inhibitors
Slack, R. J., Macdonald, S. J. F., Roper, J. A., Jenkins, R. G., & Hatley, R. J. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00284-4 · Cited by 540
Wright, R. S., Anderson, J. L., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Jneid, H., Lincoff, A. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.011 · Cited by 516
Bachmann, M., Kukkurainen, S., Hytönen, V. P., & Wehrle-Haller, B. (2019) · Physiological Reviews · doi:10.1152/physrev.00036.2018 · Cited by 407
Integrin-based therapeutics: biological basis, clinical use and new drugs
Ley, K., Rivera-Nieves, J., Sandborn, W. J., & Shattil, S. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.10 · Cited by 403
Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., Levin, T. N., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318212bb8b · Cited by 343
Integrin αvβ3‐targeted cancer therapy
Liu, Z., Wang, F., & Chen, X. (2008) · Drug Development Research · doi:10.1002/ddr.20265 · Cited by 323
Mehilli, J., Kastrati, A., Schühlen, H., Dibra, A., Dotzer, F., von Beckerath, N., Bollwein, H., Pache, J., Dirschinger, J., Berger, P. P., et al. (2004) · Circulation · doi:10.1161/01.cir.0000148956.93631.4d · Cited by 303
Marso, S. P., Lincoff, A. M., Ellis, S. G., Bhatt, D. L., Tanguay, J.-F., Kleiman, N. S., Hammoud, T., Booth, J. E., Sapp, S. K., & Topol, E. J. (1999) · Circulation · doi:10.1161/01.cir.100.25.2477 · Cited by 288
2007 WRITING COMMITTEE MEMBERS, Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828478ac · Cited by 272
Rac recruits high-affinity integrin αvβ3 to lamellipodia in endothelial cell migration
Kiosses, W. B., Shattil, S. J., Pampori, N., & Schwartz, M. A. (2001) · Nature Cell Biology · doi:10.1038/35060120 · Cited by 266
Investigators, T. A. I. I. S. (2000) · Stroke · doi:10.1161/01.str.31.3.601 · Cited by 264
Metadata
- Authors
- Tam, S. H., Sassoli, P. M., Jordan, R. E., & Nakada, M. T.
- Venue
- Circulation
- Published
- 1998-09-15
- Volume
- 98
- Issue
- 11
- Pages
- 1085-1091
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2160034002
- Cited by
- 260
- References
- 29
- FWCI
- 9.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.